Placebo for Niraparib
Phase 3
Johnson & JohnsonPlacebo for Niraparib is one of 4 therapeutic programs targeting Metastatic Castration-sensitive Prostate Cancer. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
3
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
3 competitors in Metastatic Castration-Sensitive Prostate Cancer
#DrugCompanyPhaseTrials
1Zytiga
Johnson & JohnsonPhase 3
Zejula
GGlaxo Dba Glaxosmithkline
Phase 3
Rayos
RRoxane Laboratories
Phase 3
Placebo for Niraparib
Johnson & JohnsonPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Metastatic Castration-sensitive Prostate Cancer1 trial
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Placebo for Niraparib. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 3[1]
- Company